LINC02525: A Drug Target / Disease Biomarker (G100507194)

Target Name: LINC02525

NCBI ID: G100507194

LINC02525

Other Name(s): long intergenic non-protein coding RNA 2525 | Long intergenic non-protein coding RNA 2525, transcript variant 1 | lncNB1 | TP53LC14

LINC02525: A Drug Target / Disease Biomarker

LINC02525 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. Its full name is long non-coding RNA gene 2525, and it is also known as UTR30a. LINC02525 is a potential drug target and has been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The LINC02525 gene is located on chromosome 11p36 and has a length of 214 nucleotides. It is expressed in various tissues of the body, including the brain, heart, liver, and pancreas, and is expressed in different levels in each of these tissues. LINC02525 is a nuclear protein that is involved in various cellular processes in the body.

One of the functions of LINC02525 is to regulate gene expression. It does this by binding to specific DNA sequences and preventing the translation of mRNAs that are not targeted for translation. This mechanism of regulation is known as RNA binding and is a common mechanism used by various proteins to control gene expression.

Another function of LINC02525 is to play a role in the development and progression of cancer. It has been shown to be involved in the regulation of cell cycle progression and in the development of various types of cancer. For example, studies have shown that LINC02525 is involved in the regulation of the G1/S transition, which is a critical step in the cell cycle and is involved in the development of cancer.

In addition to its role in cancer development, LINC02525 has also been shown to be involved in the regulation of other cellular processes, including cell survival and metabolism. For example, studies have shown that LINC02525 is involved in the regulation of cell survival by preventing the apoptosis of cells. This mechanism of regulation is important for the survival of cells and is involved in the development and progression of many diseases, including cancer.

LINC02525 has also been shown to be involved in the regulation of metabolism. It does this by binding to specific DNA sequences and preventing the translation of mRNAs that are not targeted for translation. This mechanism of regulation is known as RNA binding and is a common mechanism used by various proteins to control gene expression.

In conclusion, LINC02525 is a protein that is expressed in various tissues of the body and is involved in various cellular processes in the body. Its functions include regulating gene expression, cell cycle progression, cell survival, and metabolism. As a potential drug target, LINC02525 has been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Further research is needed to fully understand the role of LINC02525 in these diseases and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2525

The "LINC02525 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02525 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets